Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on dermatology. Its core business is developing and selling treatments for immune-mediated skin diseases, with ZORYVE as its commercial product platform. The company combines in-house dermatology expertise with a development strategy centered on validated biological targets and differentiated topical and systemic therapies. Arcutis currently operates as a single-reportable-segment business and is building out its own U.S. and Canadian commercialization infrastructure.

−3,1 %

90,2 %

−4,3 %

+91,3 %

3.17

2.99

— Arcutis Biotherapeutics, Inc.
%
Commercial dermatology products85% Prescription topical products sold under the ZORYVE brand for inflammatory skin diseases.
License and collaboration revenue10% Revenue from partnering agreements, primarily Sato and Huadong, tied to ex-U.S. development and commercialization rights.
Pipeline development programs5% Internal R&D programs for ARQ-234, ARQ-255, and additional ZORYVE label expansions.

Arcutis sells primarily into the prescription dermatology channel, where dermatologists and allergists prescribe ZORYVE...

  • Dermatologistsprimary

    Core prescribers for ZORYVE who treat plaque psoriasis, seborrheic dermatitis, and atopic dermatitis and value differentiated topical options.

  • Allergistsprimary

    Specialists who prescribe ZORYVE for immune-mediated dermatological conditions, especially atopic dermatitis.

  • Wholesalers and specialty pharmaciesprimary

    Distribution intermediaries that buy product for channel fulfillment, inventory management, and chargeback administration.

  • Primary care and pediatric providerssecondary

    A growing target segment for ZORYVE expansion after the end of the Kowa promotion agreement.

  • International partnerssecondary

    Licensees and collaborators in Japan, China, and other Asian markets that commercialize roflumilast formulations locally.

Arcutis is headquartered in Westlake Village, California and conducts its main commercial operations in the United...

  • •United States is the core commercial market and operating base
  • •Canada is an active second market with local commercialization infrastructure
  • •Asia is accessed mainly through licensing and collaboration partners
  • •Japan and China are specifically mentioned partner markets
  • •Westlake Village, California is the corporate headquarters
  • •No internal manufacturing footprint; supply is outsourced

Arcutis is prioritizing commercial execution for ZORYVE while continuing to expand the product's label and reach into...

01
Broaden ZORYVE prescribing beyond dermatology specialistsshort-term

A wider prescriber base can increase product uptake and reduce dependence on a narrow specialist channel.

02
Advance pipeline and label expansionsmedium-term

New indications and next-generation assets can extend the life of the franchise and diversify revenue.

03
Expand through partnerships outside North Americamedium-term

Partnering allows Arcutis to access markets without building a full international commercial organization.

Arcutis remains exposed to the execution risk typical of a commercial-stage biopharmaceutical company with a...

critical

Patent and generic erosion risk

Loss of patent protection or an at-risk generic launch could cause a rapid decline in sales of approved products.

Scope
Approved ZORYVE products
Materiality
high
high

Concentration in a small number of commercial products

The company is still building its dermatology franchise, so ZORYVE performance is central to revenue and operating leverage.

Scope
ZORYVE cream and foam franchise
Materiality
high
high

Competitive pressure from existing and new dermatology therapies

Alternative prescription and OTC products can limit demand, pricing, and reimbursement for ZORYVE.

Scope
Plaque psoriasis, seborrheic dermatitis, atopic dermatitis
Materiality
high
high

Third-party manufacturing and supply dependence

The company has no internal manufacturing capabilities and relies on external suppliers for commercial and clinical supply.

Scope
Commercial supply chain and launch readiness
Materiality
high
high

Financing and liquidity risk

Continued commercialization and R&D spending may require additional capital if operating cash flow is insufficient.

Scope
R&D, sales force expansion, manufacturing commitments
Materiality
high
medium

Cybersecurity and data privacy incidents

A breach could disrupt operations, damage intellectual property, and create remediation and notification costs.

Scope
Internal systems, vendors, collaborators, and clinical data
Materiality
medium
Net product revenue deductions
Can materially affect quarterly revenue and comparability
Sales return reserve estimation
Affects net revenue and gross-to-net trends
Inventory and cost of sales timing
Impacts gross margin and quarterly cost of sales
Deferred tax assets and valuation allowance
Affects tax expense and balance sheet presentation

Arcturus Therapeutics Holdings Inc.

ARCT · Pharmaceutical Preparations

Arcus Biosciences, Inc.

RCUS · Pharmaceutical Preparations

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Oruka Therapeutics, Inc.

ORKA · Pharmaceutical Preparations

Stoke Therapeutics, Inc.

STOK · Pharmaceutical Preparations

: 11/08/2026